RT Generic
T1 Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease
A1 Martinez-Montoro, Jose Ignacio
A1 Cornejo-Pareja, Isabel
A1 Gomez-Perez, Ana Maria
A1 Tinahones, Francisco J.
K1 non-alcoholic fatty liver disease
K1 gene polymorphism
K1 dietary intervention
K1 gene-nutrient interactions
K1 bariatric surgery
K1 pharmacotherapy
K1 De-novo lipogenesis
K1 Weight-loss
K1 Metabolic syndrome
K1 Pnpla3 p.i148m
K1 Omega-3 supplementation
K1 Rs738409 polymorphism
K1 Insulin-resistance
K1 Bariatric surgery
K1 Oxidative stress
K1 I148m variant
AB In the last decades, the global prevalence of non-alcoholic fatty liver disease (NAFLD) has reached pandemic proportions with derived major health and socioeconomic consequences; this tendency is expected to be further aggravated in the coming years. Obesity, insulin resistance/type 2 diabetes mellitus, sedentary lifestyle, increased caloric intake and genetic predisposition constitute the main risk factors associated with the development and progression of the disease. Importantly, the interaction between the inherited genetic background and some unhealthy dietary patterns has been postulated to have an essential role in the pathogenesis of NAFLD. Weight loss through lifestyle modifications is considered the cornerstone of the treatment for NAFLD and the inter-individual variability in the response to some dietary approaches may be conditioned by the presence of different single nucleotide polymorphisms. In this review, we summarize the current evidence on the influence of the association between genetic susceptibility and dietary habits in NAFLD pathophysiology, as well as the role of gene polymorphism in the response to lifestyle interventions and the potential interaction between nutritional genomics and other emerging therapies for NAFLD, such as bariatric surgery and several pharmacologic agents.
PB Mdpi
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/27076
UL https://hdl.handle.net/10668/27076
LA en
DS RISalud
RD Apr 11, 2025